Results 251 to 260 of about 79,270 (300)
Some of the next articles are maybe not open access.
Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design, 2009Erectile dysfunction (ED) has been revolutionized during the last two decades, as several treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients due to their high efficacy rates and favourable safety ...
K, Hatzimouratidis, D G, Hatzichristou
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitors: The Day After
European Urology, 2007Review the literature on phosphodiesterase type 5 inhibitors (PDE5-Is), addressing critical issues in their current and future use, assessing unanswered questions, and identifying research needs.A MEDLINE search was conducted on PDE5-Is, with emphasis on clinical trials and experience, for interpretation and analysis of their present and future role ...
Konstantinos, Hatzimouratidis +1 more
openaire +2 more sources
Phosphodiesterase type 5 inhibitors for erectile dysfunction
BJU International, 2005This is our first presentation of Great Drug Classes, and we start with a description of phosphodiesterase type 5 inhibitors and their use in erectile dysfunction. This is an in‐depth review of this class of drugs, offering the reader a description of how they work, in which conditions they may be particularly beneficial, and a ...
Culley C, Carson, Tom F, Lue
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension
New England Journal of Medicine, 2009A 46-year-old-woman presents with exertional dyspnea and syncope and receives a diagnosis of idiopathic pulmonary arterial hypertension. Treatment with sildenafil is recommended. Sildenafil and tadalafil are phosphodiesterase type 5 inhibitors that ameliorate pulmonary arterial hypertension by increasing levels of cyclic guanosine monophosphate in the ...
Stephen L, Archer +1 more
openaire +4 more sources
Phosphodiesterase Type 5 (PDE5) Inhibitors
2003Publisher Summary In recent years, the field of Phosphodiesterase Type 5 (PDE5) inhibitors has reached a state of maturity. Standard issues in medicinal chemistry, such as potency, selectivity, physico-chemical properties and oral bioavailability, have been successfully addressed with the known PDE5 inhibitors.
Helmut, Haning +2 more
openaire +2 more sources
Phosphodiesterase type 5 inhibitors and kidney disease
International Urology and Nephrology, 2015Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin-angiotensin system blockers.
Baris, Afsar +6 more
openaire +2 more sources
Can Phosphodiesterase Type 5 Inhibitors Cure Erectile Dysfunction?
European Urology, 2006To systematically analyze and review the available evidence about the potential role of chronic administration of phosphodiesterase type 5 (PDE-5) inhibitors for the cure of erectile dysfunction (ED) based on clinical and basic science data.Analysis of published full-length papers that were identified with Medline and Cancerlit from January 1993 to ...
MONTORSI , FRANCESCO +4 more
openaire +3 more sources
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
Advances in Therapy, 2009Pulmonary arterial hypertension (PAH) is a rare disease characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary arterial resistance, right heart failure, and death. The pathogenesis of PAH is multifactorial, with endothelial cell dysfunction playing an integral role.
David, Montani +8 more
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitor Abuse: A Critical Review
Current Drug Abuse Reviewse, 2011Abuse of sildenafil has been reported since its introduction in 1999 and commonly documented in combination with illicit drugs among men and women of all ages. Increased risks of sexually transmissible diseases including HIV have been associated with sildenafil use in men who have sex with men.
Gregory, Lowe, Raymond, Costabile
openaire +2 more sources